The eLitMed.hu medical portal uses computer cookies for convenient operation. Detailed information can be found in the Cookie-policy.
Hypertension and nephrology - 2016;20(04)
Content
Hypertension and nephrology
SEPTEMBER 10, 2016
Hypertension and nephrology
SEPTEMBER 10, 2016
[Hypertension and cognitive feature]
[Around authors of the literature data and our own experience of the relationship between hypertension and cognitive function. The age progresses, more and more of the dysfunction and vascular dementia. This plays a significant role in hypertension. Simple methods, tests you should regard the practice and also check this function, considering that the aging population is an unstoppable process. The effective antihypertensive treatment, blood pressure variability reduction positively affected by the deterioration of the cognitive function, especially if treatment is started as soon as possible.]
Hypertension and nephrology
SEPTEMBER 10, 2016
[Prevalence of overweight and obesity in hypertensive patients]
[Authors had performed an anthropometric analysis using a database of 2011-2013 of Hungarian Hypertension Register. They analyzed overweight and obesity in relation of age. The results were compared with similar analysis conducted in the total population 2015. They analyzed the prevalence of visceral obesity as well using the waist circumference measurement categories and these were also compared with screening data of total population. The prevalence of overweight and obesity was very high in both genders, co-occurrences exceeded 70% between 45-70 years. The prevalence was significantly higher in hypertensives, than in the total population. The prevalence of visceral obesity measured by waist circumference was also high, especially in women whose reached 50% of cases. They observed a significant difference between hypertensive and total populations In category „danger” of visceral obesity]
Hypertension and nephrology
SEPTEMBER 10, 2016
[Therapy resistant hypertension in clinical practice]
[Around 57% of Hungarian hypertensive patients did not reach the goal blood pressure. According to a paper in 2011, the prevalence of resistant hypertension is 2.9-43%. Analyzing only the therapy of hypertensive patients of an Hypertension Outpatient Clinic of the University of Szeged authors wanted to answer these main questions. How many patients were therapeutically resistant by definition? How many patients were taking 3 or more antihypertensive drugs? How many of these patients reached the goal systolis blood pressure values? How many fold drug combinations were used generally? Data were retrospectively collected from 01/01/2011 to 31/08/2011 from the electronic files of the hypertensive patients. Altogether 310 patients’ data were analyzed, of all cases only one visit. If someone returned more times during this period, only the first visit was considered. Means of two measurements were calculated. The goal SBP was 140/ mm Hg. By the definition 234/310 (76%) patients had resistant hypertension in this population (158±17/97±8 mm Hg). Three or more antihypertensive drugs were taken by 257/310 (83%) patients (136±20 mm Hg) and 134 of them (52% of 257 patients) reached the goal. A fourfold combination of antihypertensive agents was the most frequent in this population. It is advised to use multiple drug combinations to reach the goal blood pressure and it is recommended to spend enough but not longer than necessary time to find the most effective combination in every case. In resistant cases it is always necessary to investigate the background of it.]
Hypertension and nephrology
SEPTEMBER 10, 2016
[The comparative analysis of quality of life in the european countries]
[The well-being of the citizens is a determining factor of the social development in every country. The well-being is expressed in the notion of quality of life. Quality of life consists of lots of components and it is more than just being healthy, so its terrain extends far beyond the medicine. Based on a comprehensive research carried out by Eurostat the statistical office of the European Union the study intends to report about the components of the quality of life and about the findings of the survey made with the aim to map the opinions and views of the citizens about it in the different European countries. The paper deals with the relations among these components and with the comparison of the views of the countries.]
Hypertension and nephrology
SEPTEMBER 10, 2016
Hypertension and nephrology
SEPTEMBER 10, 2016
Hypertension and nephrology
SEPTEMBER 10, 2016
Hypertension and nephrology
SEPTEMBER 10, 2016
Hypertension and nephrology
SEPTEMBER 10, 2016
[Hypertension and left ventricular hypertrophy]
[Left ventricular hypertrophy (LVH) is defined as an increase in the mass of the left ventricle. In addition to the absolute increase in mass, the geometric pattern of LVH also may be important. LVH can be secondary to an increase in wall thickness, an increase in cavity size, or both. LVH as a consequence of hypertension usually presents with an increase in wall thickness. This increase in mass predominantly results from a chronic increase in afterload of LV caused by the hypertension, although there is also a genetic component. A significant increase in the number and/or size of sarcomeres is the main pathologic mechanism, but hypertension may also result in interstitial fibrosis. The estimation of mass is commonly derived from measurements obtained by echocardiography. LVH is associated with increased incidence of systolic and/or diastolic dysfunction, heart failure, myocardial infarction, ventricular arrhythmias, sudden cardiac death, aortic root dilatation, and a cerebrovascular event. The cardiovascular risk is directly related to the degree of mass. The regression of LVH is associated with a reduction in cardiovascular risk and improved cardiac function. Regression of LVH is associated with weight loss, dietary sodium restriction, and use of ACE inhibitors, ARBs, some calcium channel blockers, and some sympatholytic agents.]
Hypertension and nephrology
SEPTEMBER 10, 2016
[A new, effective tool in the treatment of hypertension in light of the available evidence]
[Hypertension is important even in the group of common diseases. Cardiovascular mortality could be significantly reduced if high blood pressure could not only be treated, but controlled as well. The newly introduced fixed combination perindopril-amlodipin-indapamide medication could be a good tool for genereal practitioners, specialists in internal medicine and cardiologists. Combined treatment with the ACE inhibitor perindopril, the new vasorelaxant type diuretic indapamide and the third generation type Ca-chanel blocker amlodipin is effective in reducing blood pressure. Besides effectivity the organ protective pleiotrop qualities (cardioprotective, plakk stabilising, antiatherosclerotic, antithrombotic, stroke preventive, endothel dysfunction reducing, renal protetcion granting) provide a long lasting beneficial impact on life expectancy and a better quality of life to the patients. If we choose the right dosage, we could raise the compliance level of patients resulting in excellent degrees of compliance. In our article we wanted to draw attention to the major evidencies which are the best acknowledgements of this triple combination although we didn’t explore all avenues.]
Hypertension and nephrology
SEPTEMBER 10, 2016
Hypertension and nephrology
SEPTEMBER 10, 2016
1.
Clinical Neuroscience
[Headache registry in Szeged: Experiences regarding to migraine patients]
21. MÁJ
2.
Clinical Neuroscience
[The new target population of stroke awareness campaign: Kindergarten students ]
21. MÁJ
3.
Clinical Neuroscience
Is there any difference in mortality rates of atrial fibrillation detected before or after ischemic stroke?
27. NOV
4.
Clinical Neuroscience
Factors influencing the level of stigma in Parkinson’s disease in western Turkey
27. SZEPT
5.
Clinical Neuroscience
[The effects of demographic and clinical factors on the severity of poststroke aphasia]
18. JÚL
1.
2.
Clinical Oncology
[Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up]
29. AUG
3.
Clinical Oncology
[Pharmacovigilance landscape – Lessons from the past and opportunities for future]
29. AUG
4.
5.